News and Announcements
Actinogen Published in British Journal of Pharmacology
- Published February 09, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical is pleased to announce the research paper: Selection and early clinical evaluation of the brain-penetrant hydroxysteroid dehydrogenade type 1 inhibitor UE2343 (Xanamem™) has been published in the British Journal of Pharmacology.
KEY TAKEAWAYS:
- These Phase I results show Xanamem™ is safe and well tolerated with no major safety issues.
- Confirm the brain penetrating properties of Xanamem™ and that it reaches the brain at concentrations predicted to inhibit excess cortisol production in the brain.
- Xanamem™ is a good candidate to further investigate as a treatment for Alzheimer’s disease.
For more information please click below.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
